Age-related Macular Degeneration (AMD) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)

Age-related Macular Degeneration Market – Report Overview

Pacific Business Consulting’s “Age-related Macular Degeneration (AMD) Market in 8MM – Market Outlook, Unmet Needs, Market Assessment and Forecast (2023-2030)” report offers a comprehensive understanding of Age-related Macular Degeneration, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The market size for Age-related Macular Degeneration (AMD) reached US$8.7 billion across the 8 Major Markets (8MM) in 2022 and is projected to experience a growth rate exceeding 10% during the forecast period from 2023 to 2030. AMD stands as a leading cause of irreversible vision loss, and while its definitive cause remains elusive, factors such as advanced age, family history, systemic conditions like hypercholesterolemia and obesity, and lifestyle choices like cigarette smoking have been identified as risk factors.

Age-related Macular Degeneration (AMD) is characterized by chronic, progressive damage to the central retina, and it stands as a significant contributor to irreversible blindness in both the Western world and Asia-Pacific countries. Currently affecting 8.7% of the global population, the wet form of AMD accounts for over 90% of severe central visual acuity (VA) loss associated with the condition.

The prevalence of AMD is expected to rise in tandem with the increasing aging population in most developed countries. Presently, there is no definitive treatment for AMD and geographic atrophy (GA), both of which result in significant and disabling central vision loss. The primary driver for the growth of the AMD market will likely be the emergence of therapies targeting geographic atrophy (GA), expanding the scope of treatable AMD cases.

The continuous development of late-stage pipeline therapies for wet AMD (wAMD) is anticipated to be a robust driving force in the 8MM market. Experts believe that Vabysmo’s potential to extend treatment intervals will become a favorable clinical feature in AMD treatment over the forecast period. The anticipated introduction of potential therapies is expected to augment the Age-related Macular Degeneration market size in the coming years, propelled by an increase in the diagnosed prevalent population of AMD.

Key players in the AMD market include Roche, Regeneron Pharmaceuticals, Apellis, Outlook Therapeutics, Abbvie, Novartis, Genentech, and Opthea Limited.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Age-related Macular Degeneration (AMD) market. It also delves into the analysis of present and prospective market competition within the global Age-related Macular Degeneration market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Age-related Macular Degeneration (AMD) market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Age-related Macular Degeneration market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Age-related Macular Degeneration (AMD)
   • Global Market Outlook: Age-related Macular Degeneration (AMD)
2. Competitive Intelligence Analysis: Age-related Macular Degeneration (AMD)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Age-related Macular Degeneration (AMD)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Age-related Macular Degeneration (AMD)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Age-related Macular Degeneration (AMD): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Age-related Macular Degeneration (AMD): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Age-related Macular Degeneration (AMD): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Age-related Macular Degeneration (AMD) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China

Copyrights and Disclaimer